Baycox Multi 50 mg/ml Oral Suspension for Cattle, Pigs and Sheep

מדינה: הממלכה המאוחדת

שפה: אנגלית

מקור: VMD (Veterinary Medicines Directorate)

מרכיב פעיל:

Toltrazuril

זמין מ:

Bayer plc

קוד ATC:

QP51AJ01

INN (שם בינלאומי):

Toltrazuril

טופס פרצבטיות:

Oral suspension

סוג מרשם:

POM-V - Prescription Only Medicine – Veterinarian

קבוצה תרפויטית:

Cattle, Pigs, Sheep

איזור תרפויטי:

Antiprotozoal anticoccidial

מצב אישור:

Authorized

תאריך אישור:

2016-10-06

מאפייני מוצר

Revised: October 2020
AN: 00937/2020
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Baycox Multi 50 mg/ml oral suspension for Cattle, Pigs and Sheep
For FI, DK, IS, SE: Baycoxine vet 50 mg/ml oral suspension for Cattle,
Pigs and
Sheep
For NO: Baycoxine vet.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 ml contains:
ACTIVE SUBSTANCE:
Toltrazuril 50 mg
EXCIPIENTS:
Sodium benzoate (E211) 2.1 mg
Sodium propionate (E281) 2.1 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oral suspension
White or yellowish suspension
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle (calves: dairy calves, beef suckler, bull beef), Pigs (Piglets,
3-5 days old),
Sheep (lambs).
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Cattle: For the prevention of clinical signs of coccidiosis and
reduction of coccidia
shedding in calves on farms with a confirmed history of coccidiosis
caused by
_Eimeria bovis_ or _Eimeria zuernii_.
Pigs: For the prevention of clinical signs of coccidiosis in neonatal
piglets (3-5 days
old) on farms with a confirmed history of coccidiosis caused by
_Cystoisospora suis_.
Page 1 of 7
Revised: October 2020
AN: 00937/2020
Sheep: For the prevention of clinical signs of coccidiosis and
reduction of coccidia
shedding in lambs on farms with a confirmed history of coccidiosis
caused by _Eimeria_
_crandallis_ and _Eimeria ovinoidalis_.
4.3
CONTRAINDICATIONS
Do not use in cases of known hypersensitivity to the active substance
or any of the
excipients.
4.4
SPECIAL WARNINGS
It is recommended to treat all animals in a pen.
Hygienic measures may reduce the risk of coccidiosis. It is therefore,
recommended
to improve concomitantly the hygienic conditions in the concerned
facility, particularly
dryness and cleanliness.
To obtain maximum benefit, animals should be treated before the
expected onset of
clinical signs, i.e. in the prepatent period.
To alter the course of an established clinical coccidial infection, in
individual animals
already showing signs of diarrh